Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy

NCT03739840 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT03739840
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03739840 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy
Lead sponsor
UCB Biopharma SRL
Phase
Phase 3
Overall status
Terminated
Start date
March 6, 2019
Completion date
September 28, 2020
Enrollment
232 (actual)
Sites
141

Conditions

As the registry lists them; a condition with its own page is linked.

drug-resistant epilepsy, focal-onset seizures